Breaks Categories: News

WednesdayAug 07, 2024 12:31 pm

NetworkNewsBreaks – Clene Inc. (NASDAQ: CLNN) Releases Q2 2024 Financial Results, Provides Updates

Clene (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”), today released its Q2 2024 financial results. In addition, the company provided recent updates on its CNM-Au8(R) programs evaluating the use of CNM-Au8 for the treatment of ALS and Rett Syndrome. “We are approaching our next FDA interaction focused on the regulatory path forward to potentially bring CNM-Au8 to people living with ALS,” commented Rob Etherington, President and…

Continue Reading

WednesdayAug 07, 2024 12:17 pm

NetworkNewsBreaks – Trump Media & Technology Group (NASDAQ: DJT) Announces ‘Milestone’ Launch of TV Streaming on iOS Devices

Trump Media & Technology Group (NASDAQ: DJT), operator of the social-media platform Truth Social, has added linear TV streaming functionality on iOS devices. According to the announcement, iOS users can update their Truth Social apps through the Apple App Store to access TV streaming. After the app has been updated, they can use the new feature by clicking on the Truth+ streaming icon, which looks like a TV and which enables users to stream content as standalone channels or in a separate picture-in-picture (“PiP”) window while on the Truth Social platform. The addition of streaming on iOS devices is a…

Continue Reading

WednesdayAug 07, 2024 10:40 am

NetworkNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Release Promising Clinical Data As Global Alzheimer’s Disease Therapeutics Market Grows

Annovis Bio (NYSE: ANVS), a late-stage, clinical-drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), has released preclinical data from a study of its lead compound, buntanetap. According to the announcement, the study showed the synergistic effect of buntanetap combined with the glucagon-like peptide 1 (GLP-1) agonist dulaglutide (Trulicity[R]) in enhancing cognition in a mouse model of Alzheimer’s disease. The news comes as the global Alzheimer’s Disease Therapeutics Market is experiencing significant growth as an escalating aging population along with earlier and more accurate diagnoses contribute to more people facing the disease.…

Continue Reading

TuesdayAug 06, 2024 2:03 pm

NetworkNewsBreaks – Finovate Shares FinovateFall Agenda Highlights

Finovate, a research and events company focused on innovation in financial and banking technology, is hosting FinovateFall, a pioneering fintech conference focused on the digital future of financial institutions. The event is slated for Sept. 9–11, 2024, in New York City. According to the announcement, the three-day fintech conference is “by and for executives and thought leaders who are revolutionizing the financial services industry.” The event agenda includes presentations from more than 120 renowned speakers and subject matter experts and more than 60-plus live product demonstrations from a range of fintech companies, including startups to established players. Speakers for the…

Continue Reading

TuesdayAug 06, 2024 1:01 pm

NetworkNewsBreaks – McEwen Mining Inc. (NYSE: MUX) (TSX: MUX) Schedules Conference Call to Discuss Q2 2024 Results

McEwen Mining (NYSE: MUX) (TSX: MUX), a gold and silver producer with operations in Nevada, Canada, Mexico and Argentina, is announcing the date for its upcoming conference call and webcast. The call is slated to begin at 11 a.m. EDT on Aug. 8, 2024. During the call, management will discuss the company’s second-quarter 2024 financial results as well as project developments. The call will also include time for questions and answers, with those on the call able to ask questions directly over the phone. Those wanting to participate can dial (888) 210-3454 toll free in North American, then use conference…

Continue Reading

TuesdayAug 06, 2024 12:48 pm

NetworkNewsBreaks – Clene Inc. (NASDAQ: CLNN) Submits New CNM-Au8 Biomarker, Clinical Efficacy Data to FDA

Clene (NASDAQ: CLNN), a late-stage biopharmaceutical company focused on protecting mitochondrial health and neuronal function to treat neurodegenerative diseases, and its wholly owned subsidiary Clene Nanomedicine Inc., have submitted new data to the U.S. Food and Drug Administration (“FDA”). The data is regarding CNM-Au8(R) biomarker and clinical efficacy information, including post hoc analyses from two phase 2 clinical trials of CNM-Au8 for the treatment of ALS; the trials were conducted independently. According to the announcement, this new data is in addition to original data the company has discussed with FDA and is intended to guide the planned FDA Type C interaction; that…

Continue Reading

TuesdayAug 06, 2024 12:36 pm

NetworkNewsBreaks – Astiva Health Announces Launch of Investor Relations Website to Facilitate Transparent, Effective Communication

Astiva Health, a leader in innovative and culturally aware healthcare solutions, today announced the launch of its new Investor Relations website. The launch marks a significant step and milestone in the company’s journey towards becoming a public company. It emphasizes Astiva Health’s commitment to maintaining transparent and effective communication and building strong relationships with investors, stakeholders, and the broader financial community. The platform will offer easy access to detailed company overviews and strategic vision, financial reports and performance metrics, press releases and media coverage, corporate government practices, and upcoming events and presentations. “We are excited to launch our Investor Relations…

Continue Reading

TuesdayAug 06, 2024 12:07 pm

NetworkNewsBreaks – Snap Inc. (NYSE: SNAP) Faces Downturn Despite Revenue Growth

Snap (NYSE: SNAP), the parent company of Snapchat, faced a significant downturn in its stock value during after-hours trading following its second-quarter earnings report for 2024. Despite a 16% year-over-year increase in total revenue, reaching $1.24 billion, the decline in the company’s stock reflects investor concerns about Snap’s future growth prospects, especially given the deceleration from the 21% growth recorded in the first quarter of 2024. The mixed financial results also highlighted a net loss of $249 million, which, despite being a 34% improvement from the previous year, still raises questions about the company’s profitability. Snap’s user engagement metrics, however, paint a more positive picture. The Daily Active…

Continue Reading

TuesdayAug 06, 2024 11:34 am

NetworkNewsBreaks – Blockchain Futurist Conference Plays Pivotal Role in Shaping the Future of Web3, Finance

Blockchain Futurist Conference is Canada’s largest and most high-profile Web3, blockchain and cryptocurrency event. Serving as an essential platform for ideas and collaboration, the conference has proven to be an important global gathering helping shape the future of Web3. This year’s event is scheduled for August 13-14, 2024, in Toronto, Canada; the event will run alongside ETHToronto and ETHWomen Hackathons, the largest web3 hackathons in Canada. During Futurist 2023, reporter Daniel Bruno solicited quotes from onsite attendees experiencing the excitement of the event. What they said sets the tone for this year’s dynamic must-attend Blockchain Futurist Conference. “We have attended…

Continue Reading

TuesdayAug 06, 2024 11:13 am

NetworkNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Reports on Clinical Data Showing Lead Compound Combined with GLP-1 Agonist Enhances Cognition

Annovis Bio (NYSE: ANVS), a late-stage, clinical-drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), is reporting preclinical data regarding its lead compound, buntanetap. According to the announcement, the results show the synergistic effect of buntanetap when combined with the glucagon-like peptide 1 (“GLP-1”) agonist dulaglutide (Trulicity[R]) in a mouse model of Alzheimer’s disease. Based on data gathered in 2018 showing that buntanetap fully restored memory, learning and synaptic potentiation in an Alzheimer’s mouse model, Annovis recently studied whether buntanetap combined with the GLP-1 agonist dulaglutide produced a synergistic effect in the…

Continue Reading